comparison in patients in the high HIV RNA stratum due to a shorter time to virologic failure for ABC/3TC than TDF/FTC [5] . Of continued interest was whether ABC/3TC and TDF/FTC given with EFV or ATV/r provided comparable antiviral activity for patients from the low HIV RNA stratum. In addition, data on the comparison between NRTIs with the individual third drugs from the high HIV RNA stratum were not reported.
METHODS

Study Design
The study population and study design have been previously reported [5] . Because pretreatment resistance genotype testing was not recommended in HIV treatment guidelines until 1 December 2007, screening resistance testing was not required before study entry in all patients. The planned duration of the study was 96 weeks from enrollment of the last subject.
Patients were randomly assigned to receive fixed-dose ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg with ATV/r 300 mg/ 100 mg or EFV 600 mg, along with matching placebo for the other NRTI. Unblinding of the TDF/FTC and ABC/3TC components was allowed for site-investigator-suspected NRTI treatmentlimiting adverse event, virologic failure, or pregnancy. Adverse events and laboratory events were assessed by the investigators and scored with the use of the Division of AIDS Table for grading the severity of adult and pediatric events, version 2004.
Randomization was stratified by screening HIV RNA level (,10 5 vs $10 5 copies/mL), and used a permuted-block design with dynamic balancing according to the main site. Study evaluations were completed at screening/pre-entry; entry; weeks 4, 8, 16, 24 ; and every 12 weeks thereafter and regardless of antiretroviral modification or study endpoint. After screening, plasma HIV RNA (Roche Amplicor Monitor assay, version 1.5; Roche Diagnostic System) was measured at a central laboratory (Department of Pathology, Johns Hopkins University). At the time of virologic failure, genotypic resistance (baseline and failure specimens) was performed at Stanford University. Major mutations at baseline and virologic failure were defined as those listed by the International AIDS Society USA [6] , as well as T69D, L74I, and G190C/E/Q/T/V for reverse transcriptase and L24I, F53L, I54V/A/T/S, G73C/S/T/A, and N88D for protease.
Statistical Analysis
The primary efficacy endpoint was time from randomization to virologic failure, defined as confirmed HIV RNA level $1000 copies/mL at or after 16 weeks and before 24 weeks, or $200 copies/mL at or after 24 weeks. The primary hypothesis for the NRTI components was that ABC/3TC was equivalent to TDF/FTC with ATV/r or EFV. The study design defined that overall, the 2 regimens were considered equivalent if the 2-sided 95% confidence interval (CI) for the hazard ratio (HR) on virologic failure was between 0.71 and 1.40. Equivalence boundaries were not specified a priori within each HIV RNA stratum.
The primary tolerability endpoint was time from initiation of randomized treatment to any regimen modification. The primary safety endpoint was time from initiation of randomized treatment to the first occurrence of a grade 3 or 4 sign, symptom, or laboratory abnormality that was at least 1 grade higher than baseline. The protocol specified that isolated unconjugated hyperbilirubinemia and creatine kinase level elevations would be excluded from the safety endpoints.
Analyses of efficacy data were intention-to-treat (ITT), including all eligible randomized subjects. Analyses of safety data were as-treated (AT) while on the initial randomized regimen. Time-to-event survival distributions were estimated with the Kaplan-Meier method, and comparisons for differences were assessed by means of 2-sided log-rank tests. HRs were estimated with Cox proportional-hazards models and overall analysis were stratified by screening HIV RNA level. Changes in CD4
1 cell count and as-treated fasting lipid levels and calculated creatinine clearance at weeks 48 and 96 were compared with a WilcoxonMann-Whitney test. Summaries of the high HIV RNA stratum data are restricted to the blinded study medication follow-up and were censored at the time of the DSMB recommendation implementation. Study conduct and safety data were reviewed at 2 planned annual DSMB reviews. Early-stopping guidelines for inferiority were prespecified, with a regimen considered to be inferior if the 99.95% 2-sided CI for the HR for virologic failure did not include 1.0.
The first DSMB efficacy review on 29 January 2008 noted a higher virologic failure rate for regimens containing ABC/3TC compared with TDF/FTC. Following a DSMB-requested additional prespecified secondary factorial analysis, it was noted that the excess in virologic failure occurred within the high HIV RNA stratum. The DSMB recommend that the blinded NRTI comparison in the high HIV RNA stratum be discontinued, and that the patients be unblinded to their NRTI regimen assignment. An additional interim review was requested by the DSMB for May 2008, and the DSMB recommended continuation through planned end of follow-up.
P values and confidence intervals are 2-sided and nominal with no adjustment for interim analyses or multiple comparisons. The significance level for modification of treatment effect was prespecified at 0.10. Analyses were performed with the use of SAS software, version 9 (SAS) and with S-Plus software, version 6 (Insightful Corp.).
RESULTS
Enrollment, Disposition of Patients, and Demographics
Study enrollment was from September 2005 to December 2007. Of the 1857 eligible patients enrolled, 1060 patients were randomized in the low HIV RNA stratum and followed for a median of 136 weeks (25th, 75th percentile 106, 170, respectively). Figure 1 summarizes the enrollment and disposition of patients in the low HIV RNA stratum. Demographic and baseline health characteristics are noted in Table 1 .
Primary Virologic Outcome in Low the HIV RNA Stratum
The estimated HR for virologic failure of ABC/3TC versus TDF/ FTC with ATV/r was 1.25 (95% CI, 0.76, 2.05), with virologic failures occurring in 35 and 29 patients, respectively. In a posthoc analysis, the percentages without virologic failure at week 96 for ABC/3TC and TDF/FTC, respectively, were 88.3% and 90.3% for a difference of 22.0% (95% CI, 27. 5, 3.4) . With EFV, the estimated HR for virologic failure of ABC/3TC versus TDF/FTC was 1.23 (95% CI, 0.77, 1.96) , with virologic failures occurring in 39 and 33 patients, respectively. The percentages without virologic failure at week 96 for ABC/3TC and TDF/FTC, respectively, were 87.4% and 89.2% for a difference of 21.8% (95% CI: 27.5, 3.9). Kaplan-Meier plots of the time to confirmed virologic failure are shown in Figure 2A .
Sensitivity analyses that also included unconfirmed virologic failures and the first event of unconfirmed virologic failure, death, or premature discontinuation of follow-up showed results similar to the primary efficacy analysis.
Secondary Virologic Analyses in the Low HIV RNA Stratum A cross-sectional analysis of available data evaluated the proportion of patients with HIV RNA ,50 copies/mL at week 96, regardless of previous virologic failure or drug regimen change. The proportions for ATV/r were 89% with ABC/3TC and 93% Figure 1 . Enrollment, randomization, and disposition of patients with screening HIV RNA ,10 5 copies/mL. Patients were to remain in follow-up regardless of whether antiretroviral therapy was modified; therefore, study follow-up and treatment modification disposition are both presented. Reasons for treatment modification are split into (number before, number after, number without protocol-defined virologic failure) to summarize the amount of censoring of primary efficacy endpoints in as-treated analyses.* Nucleoside reverse transcriptase inhibitors were blinded through 25 February 2008 for persons with HIV-1 RNA levels of 100 000 copies/mL or more at screening and until final visits starting 1 July 2009 for those with HIV-1 RNA levels less than 100 000 copies/mL at screening. Death was censored for premature study discontinuation and counted as a reason for treatment discontinuation if there was no previous regimen modification. Site closure was censored for premature study and treatment discontinuation. à Site-declared virologic failure was by clinical determination of the site investigator, whereas protocol-defined virologic failure was determined strictly by the quantitative definition set forth in the protocol. Numbers may differ because not all patients who had protocol-defined virologic failure modified the regimen, or the drug modification may have been attributed to another reason, such as``nonadherent with medications or visits. '' with TDF/FTC for a difference of 24.6% (95% CI, 29.9, 0.8). For EFV, the proportions were 91% and 92% for ABC/3TC and TDF/FTC, respectively, for a difference of 20.6% (95% CI, 26.0, 4.8, Figure 2B ).
A prespecified secondary endpoint of time to regimen failure demonstrated for the low HIV RNA stratum a significantly shorter time to regimen failure for ABC/3TC than TDF/FTC with ATV/r-(HR 1.40; 95% CI, 1.05, 1.87, P 5 .02) or EFV(HR 1.44; 95% CI, 1.09, 1.89; P 5 .01, Figure 2C ).
Primary Virologic Outcomes at the Time of the DSMB Action
For the NRTI comparison in the high HIV RNA stratum with ATV/r, there was a shorter time to virologic failure with ABC/ 3TC (32 failures) than TDF/FTC (15 failures), HR 2.22 (95% CI, 1.19, 4.14) . Similarly, there was a shorter time to virologic failure for ABC/3TC (25 failures) than TDF/FTC (11 failures), HR 2.46 (95% CI, 1.20, 5.05) with EFV, Figure 2D . There was no significant evidence that this treatment effect differed by either ATV/r or EFV (P 5 .82).
At the time of the DSMB action combining high and low HIV RNA strata, ATV/r with ABC/3TC versus TDF/FTC had an estimated HR for virologic failure of 1.48 (95% CI, 0.95, 2.31) . Within the EFV groups, the time to virologic failure for ABC/ 3TC was significantly shorter than TDF/FTC, HR 1.98 (95% CI 1.22, 3.20) . There was no significant interaction by ATV/r or EFV (P 5 .38) . When the NRTI comparison was combined across ATV/r and EFV regimens (factorial analysis) for all patients (high and low HIV RNA stratum), the HR for virologic failure was 1.70 (95% CI, 1.23, 2.35 Within the ATV/r regimens, the time to first antiretroviral drug modification was significantly shorter for ABC/3TC than TDF/ FTC, HR 1.43 (95% CI, 1.06, 1.92, P 5 .018, Figure 3A ). Similarly, within the EFV regimens, the time to first antiretroviral drug modification was significantly shorter for ABC/3TC than TDF/FTC, HR 1.48 (95% CI, 1.12, 1.95, P 5 .005). The most common reasons for drug modification were toxicity/clinical event, virologic failure, and noncompliance with study medications, with distributions of reasons between study arms shown in Figure 1 . Within the ATV/r and EFV regimens, the secondary tolerability endpoint of time to first modification of the NRTIs was significantly shorter for ABC/3TC than TDF/FTC, HR 1.57 (95% CI 1.14, 2.16, P 5 .006) and HR 1.84 (95% CI 1.36, 2.51, P , .0001), respectively. When this analysis was restricted to reasons other than suspected abacavir-associated hypersensitivity reaction, the time to first NRTI modification was significantly (2) 10 (1) 32 (2) Native American 12 (1) 2 (0) 14 (1) More than 1 race 6 (1) 10 (1) 16 (1 Genotype before entry, n (%) 489 (46) 341 (43) 830 (45) History of AIDS, n (%) 123 (12) 189 (24) 312 (17) Differences between low and high HIV RNA stratum: P , .05 for sex, race/ethnicity, age, CD4 1 cell count, calculated creatinine clearance, and history of AIDS. Number missing baseline race or ethnicity category 5, and CD4
1 cell count 1.
Abbreviation: HIV indicates human immunodeficiency virus. a Race or ethnicity group was self reported.
b Baseline RNA is calculated as mean of pre-entry and entry log 10 (copies/mL). Baseline CD4 1 count is calculated as the mean of pre-entry and entry values.
shorter for ABC/3TC than TDF/FTC with EFV, HR 1.45 (95% CI 1.05, 2.01, P 5 .02) but not with ATV/r, HR 1.24 (95% CI 0.89, 1.75; P 5 .20).
Unblinding of NRTIs in the Low HIV RNA Stratum
For ATV/r, unblinding of NRTIs for suspected drug hypersensitivity occurred in 23 and 11 patients randomized to ABC/3TC and TDF/FTC, respectively; for EFV, suspected hypersensitivity unblindings occurred in 32 patients randomized to ABC/3TC and 8 to TDF/FTC. After unblinding, 1 patient experienced a severe hypersensitivity reaction when rechallenged with TDF/ FTC [7] . There were 9 unblinding requests of TDF/FTC in the low HIV RNA stratum for renal-related reasons, 4 (1.5%) randomized to ATV/r, and 5 (1.9%) to EFV.
Safety Endpoints in the Low HIV RNA Stratum
Overall, 339 patients (32%) experienced a safety event while on their initial regimen. Time to first safety event was not significantly different for ABC/3TC or TDF/FTC with ATV/r (HR 1.13; 95% CI, 0.83 to 1.54, P 5 .44) and was shorter for ABC/3TC than TDF/FTC when given with EFV (HR 1.38; 95% CI, 1.03, 1.85, P 5 .03, Figure 3B ). Safety events are listed in Table 2 , with most events occurring in the general body (12%) and metabolic (7%) categories.
Clinical and Laboratory Events in the Low HIV RNA Stratum
There were 10 deaths in the low HIV RNA stratum, which included 4 for ATV/r with ABC/3TC (non-Hodgkin's lymphoma, myocardial infarction, automobile accident, drug overdose/ suicide) and none with TDF/FTC; 3 deaths for EFV with ABC/ 3TC (bladder carcinoma, hepatic carcinoma, unknown) and 3 with TDF/FTC (bacterial pneumonia, stroke, Mycobacterium avium complex). Cardiovascular events were reported in 29 for ABC/3TC, and 34 for TDF/FTC (Table 3) . Bone fractures were reported in 3% receiving ABC/3TC with ATV/r, 4% TDF/FTC with ATV/r, 6% ABC/3TC with EFV, and 5% TDF/FTC with EFV. Site-reported incidence of renal disease occurred in 4% with ABC/3TC (4% with both ATV/r and EFV) and 2% for TDF/FTC (3% with ATV/r and 2% with EFV). Data on change from Figure 2 . A, Time to protocol-defined virologic failure in those with screening plasma HIV RNA,10 5 copies/mL. B, Proportion of patients in low HIV RNA stratum with HIV RNA level ,50 copies/mL and 95% binomial confidence intervals at each study week where analysis includes patients with available data, regardless of whether they had previously switched therapy or met criteria for virologic failure. C, Time to regimen completion (time to the first occurrence of either confirmed virologic failure or discontinuation of initially randomized regimen) in low HIV RNA stratum. D, Time to protocoldefined virologic failure in the high HIV RNA stratum.
baseline in calculated creatinine clearance to weeks 48 and 96 were available for the 75% and 66% of patients who started study regimen, respectively. Statistically significant improvements from baseline to weeks 48 and 96 was found within all treatment arms (all P , .018) at both time points, except for ATV/r with TDF/ FTC group at week 96 (P 5 .14). With ATV/r, there were significant differences in the distribution of change from baselinecalculated creatinine clearance between ABC/3TC and TDF/FTC at both week 48 (median 13.3 vs 23.1 mL/min, P , .001) and week 96 (median 15.2 mL/min vs 23.1 mL/min, P , .001). For EFV with ABC/3TC vs TDF/FTC, there was no significant difference in the change from baseline in calculated creatinine Figure 3 . In low HIV RNA stratum, (A) Time to tolerability endpoint, defined as first change in regimen; and (B) time to first primary safety endpoint, defined as first grade 3 or 4 sign, symptom, or laboratory abnormality while on initial randomized treatment that was at least 1 grade higher than baseline, excluding hyperbilirubinemia and elevation in the creatine kinase level.
clearance at week 48 (median 12.6 mL/min vs 13.3 mL/min, P 5 .83) or week 96 (17.0 mL/min vs 14.5 mL/min, P 5 .15).
For patients on a randomized treatment regimen with fasting samples (range 154-188 patients per treatment arm), changes from baseline in lipids levels were generally greater with ABC/ 3TC than TDF/FTC. With ATV/r, median changes for ABC/3TC vs TDF/FTC at week 48 respectively were total cholesterol, 30 vs 8 mg/dL (P , .001); low-density lipoprotein (LDL) cholesterol, 14 vs 0 mg/dL (P , .001); high-density lipoprotein (HDL) cholesterol, 7 vs 4 mg/dL (P, .001); and triglycerides, 27 vs 14 mg/dL (P 5 .004). With EFV, changes in total cholesterol were 34 vs 19 mg/dL (P , .001); LDL cholesterol, 17 vs 6 mg/dL (P ,.001); HDL cholesterol, 12 vs. 9 mg/dL (P 5 .006); and triglycerides, 12 vs 13 mg/dL (P5 .49), respectively. There was no significant difference between NRTIs in the change in the total:HDL cholesterol ratio. Results were similar at week 96.
Resistance
In the low HIV RNA stratum, 136 patients had virologic failure, with resistance data available at baseline and failure in all but 2 patients (Table 4) . Baseline major resistance was present in 13 (10%) patients with virologic failure. Among 122 virologic failures with no major resistance at baseline, there was no significant difference in the occurrence of major resistance Metabolic, n (%) 22 (8) 19 (7) 24 (9) 13 (5) 78 (7) Total cholesterol (fasting), n 4 21 (8) 16 (6) 12 (5) 12 (5) 61 (6) Diarrhea/loose stool, n 2 4 8 2 . ALT, n 7 1 1 6 . Nausea and/or vomiting, n 6 3 3 1 . Neuropsychological, n (%)
8 (3) 1 (,1) 16 (6) 14 (5) 39 (4) Depression, n 3 0 3 7 . General body, n (%)
29 (11) 30 (11) 42 (16) 30 (11) 131 (12) Ache/pain/discomfort, n 20 11 12 17 . Fever, n 6 7 6 1 . Asthenia/fatigue, n 3 3 7 3 . Rash/allergic reaction, n 2 2 5 2 . Headache, n 3 3 6 1 . Hematologic, n (%) 1 ( ,1) 7 (3) 4 (2) 7 (3) 19 (2) Neutrophil count, n 1 6 4 7 .
Events are listed if .2% of patients had an event in a major category with frequency selected if $5 in any study arm.
Abbreviations: ABC indicates abacavir; TDF, tenofovir DF; ATV/r, atazanavir/ritonavir; EFV, efavirenz; LDL, low-density lipoprotein; ALT, alanine aminotransferase. a Includes patients who started study medication. (6) 15 (6) 14 (5) 19 ( Non-AIDS malignancies, n (%) 13 (5) 9 (3) 15 (6) 10 (4) Renal, n (%) 10 (4) 7 (3) 10 (4) 5 (2) Bone fractures, n (%) 7 (3) 10 (4) 15 (6) 13 (5) Abbreviations: ABC indicates abacavir; TDF, tenofovir DF; ATV/r, atazanavir/ritonavir; EFV, efavirenz. a Defined as coronary artery disease, infarct, ischemia, angina, cerebrovascular accident, transient ischemic attack, or peripheral vascular disease.
mutations between ABC/3TC and TDF/FTC when given with either ATV/r or EFV.
Resistance data for patients in the high HIV RNA stratum with virologic failure at the time of the DSMB review are shown in Table 5 . When given with ATV/r, the emergence of major NRTI resistance mutations was not significantly different with ABC/3TC (6 of 29) or TDF/FTC (3 of 14, P 5 1.0 of failures and P 5 .34 of randomized). With EFV, major NRTI resistance emerged in 15 of 23 and 2 of 8 randomized to ABC/3TC and TDF/FTC, respectively (P 5 .10 of failures and P 5 .002 of randomized).
Adherence
Data on self-reported adherence were collected at weeks 8 and 24, and every 24 weeks thereafter. In the low viral load stratum, adherence was high at weeks 48 and 96, with perfect self-reported adherence over the past week in 87%-92% of patients in the ABC/3TC and TDF/FTC arms, respectively, with no significant difference between ABC/3TC and TDF/FTC with EFV or ATV/r at these time points (P $ .14). In the high viral load stratum, a significantly smaller proportion of patients in the ABC/3TC-than TDF/FTC-treated patients at week 48 had perfect adherence with ATV/r (87% vs 94%, P 5 .05); this was not significantly different with EFV (91% vs 93%, P 5 .63).
DISCUSSION
In this randomized, partially blinded study, the time to virologic failure for patients in the low HIV RNA stratum (,10 5 copies/mL) was similar between ABC/3TC and TDF/FTC when combined with ATV/r or with EFV. Time to first regimen modification was shorter for ABC/3TC than TDF/FTC with both ATV/r and EFV, and time to first safety event was shorter for ABC/3TC with EFV. The virologic failure results stand in contrast to the outcome previously reported for the high HIV RNA stratum where the difference in virologic efficacy between the NRTIs prompted an independent DSMB to recommend cessation of the comparison in this group of patients [5] . Further data presented here demonstrate that the efficacy difference in the high RNA stratum was seen when these NRTI combinations were given with either ATV/r or EFV. There are several possible explanations, not mutually exclusive, for the difference in virologic outcomes between ABC/3TC and TDF/FTC in the 2 HIV RNA strata in this study. For the high HIV RNA stratum, a higher rate of NRTI and NNRTI mutations in those randomized to ABC/3TC than TDF/FTC with EFV was found, a difference not seen in the low HIV RNA stratum, suggesting that ABC/3TC may have a lower barrier to resistance than TDF/FTC. This finding is also consistent with the lower rate of selection of M184V/I mutations in some studies (13) 29 (11) 39 (15) 33 ( 
Protease-associated
Abbreviations: ABC/3TC indicates abacavir/lamivudine; TDF/FTC, tenofovir DF/emtricitabine; ATV/r, atazanavir/ritonavir; EFV, efavirenz; N, number of mutations.
a Analyses were intent-to-treat with some patients having switched from originally assigned regimen prior to developing protocol-defined virologic failure.
b Major mutations were defined as those listed by the International AIDS Society-USA [8] , as well as T69D, L74I, and G190C/E/Q/ T/ V for reverse transcriptase, and L24I, F53L, I54V/A/T/S, G73C/S/T/A, and N88D for protease.
c Total may not add up to 100% because some patients had .1 mutation.
d Major mutations targeted but not observed in the low screening HIV RNA stratum were (1) NRTI: K65R, K70R/E, Y115F, Q151M, L210W, T215F/Y, K219E, and T69D, and (2) NNRTI: L100I, V106A/M, Y181C/I, and G190C/T/V. e Other observed targeted major mutations in the low screening HIV RNA stratum include (1) NRTI: M41L and D67N, and (2) NNRTI: V108I, Y188C/H, and P225H.
when FTC and 3TC are compared [9] . Owing to greater intrinsic antiviral activity of FTC over 3TC, the combination of TDF/FTC might be more potent than ABC/3TC [8] . Additionally, minority species of some mutationsdmost notably a change from methionine to valine at residue 184 in HIV reverse transcriptasedphenotypically increases resistance to ABC, but enhances susceptibility to TDF [10] . Importantly, MI84V was the most common NRTI resistance mutation observed in this study with virologic failure. Pharmacokinetic differences between ABC/3TC and TDF/FTC could also contribute, as the intracellular half-lives of both TDF and FTC are longer than ABC and 3TC [8, 11] ; this difference could be particularly important in patients with suboptimal adherence [12] . While self-reported adherence was largely excellent among most of the study subjects, perfect adherence favored TDF/FTC over ABC/3TC in the high viral load stratum. Many of these factors might lead to a higher rate of virologic failure for ABC/ 3TC than TDF/FTC when the HIV RNA is high, but not be of a sufficient magnitude to influence virologic outcomes in patients who initiate treatment with lower viral loads. These hypotheses are being explored in resistance and pharmacokinetic studies of A5202. When given with EFV, ABC/3TC was associated with a faster time to a safety endpoint. This difference was not observed with ATV/r. The bulk of this effect related to lipid elevations and nonspecific body aches. Two drug-specific side effects of interest with TDF and ABC are renal toxicity and cardiovascular disease, respectively. There was a significant difference in change from baseline in calculated creatinine clearance for TDF/FTC compared with ABC/3TC when given with ATV/r; these results are consistent with other studies that have shown an influence of ritonavir-boosted protease inhibitors on TDF-related changes in renal function [13, 14] . Importantly, the magnitude of this change within the TDF/FTC treatment arm was small and not statistically different from baseline, and there were few treatment modifications for renal-related toxicities. This difference between TDF/FTC and ABC/3TC in change in calculated creatinine clearance was not observed when combined with EFV. Notably, cardiovascular events were infrequent in all treatment arms. 
b Major mutations were defined as those listed by the International AIDS Society USA [8] , as well as T69D, L74I, and G190C/E/Q/ T/ V for reverse transcriptase, and L24I, F53L, I54V/A/T/S, G73C/S/T/A, and N88D for protease.
d Major mutations targeted but not observed in the high screening HIV RNA stratum at the time of the DSMB action were (1) NRTI: M41L, K70E/R, Q151M, L210W, T215F/Y, and T69D, and (2) NNRTI: Y181I, Y188C/H, and G190C/T/V. e Other observed targeted major mutations in the high screening HIV RNA stratum at the time of the DSMB action include (1) NRTI: D67N, Y115F, K219E, and (2) NNRTI: V106A/M, V108I, and P225H.
As observed in the high HIV RNA stratum, patients in the low stratum randomized to ABC/3TC were significantly more likely to discontinue randomized NRTIs than those randomized to TDF/FTC with ATV/r and with EFV. Suspected drug hypersensitivity reactions comprised 44 of the 196 ABC/3TC discontinuations in those patients receiving ABC/3TC-containing regimens. It is notable that testing for HLA-B*5701 allele, which is associated with hypersensitivity reactions to ABC [15] , was permitted but not routinely performed during this study. As HLA-B*5701 testing is now standard-of-care prior to initiating an ABC-containing regimen, it is likely that the difference in tolerability between the 2 NRTI strategies would be smaller.
A5202 is the largest randomized study comparing ABC/3TC and TDF/FTC [16, 17] Nonetheless, this study has several potential limitations. With the high HIV RNA stratum stopped early, investigators and patients in the lower stratum may have chosen to stop blinded treatment. However, there was little evidence that this influenced the low HIV RNA stratum, as few patients changed the NRTIs due to clinician or participant request after the DSMB action. Baseline genotypic resistance testing in treatment-naive patients was not standard of care when A5202 started, and hence only 45% underwent testing prior to enrollment. Finally, testing for the HLA-B*5701 allele was infrequently performed prior to beginning ABC-containing therapy, and this likely influenced some of the safety and tolerability endpoints.
In summary, this large comparative clinical trial of ABC/3TC and TDF/FTC combined with either ATV/r or EFV found little difference in virologic efficacy between the 2 NRTI strategies when the screening HIV RNA was ,10 5 copies/mL. By contrast, in the high RNA stratum, the time to virologic failure was faster with ABC/3TC than TDF/FTC with either ATV/r or EFV; furthermore, safety and tolerability generally favored TDF/FTC over ABC/3TC. Overall, these results support recent treatment guidelines that TDF/FTC be the preferred initial NRTI combination in treatment-naive patients, with ABC/3TC being an effective alternative choice. Several factors should be considered when selecting the optimal initial NRTI combination for an individual patient, including baseline HIV RNA level, HLA-B*5701 status, coinfection with hepatitis B, renal function, and lipid parameters. 
